Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid 22110, Jordan.
Clinical Genomics Unit, Department of Genetics and Cell Biology, Maastricht University, 6229 ER Maastricht, The Netherlands.
Int J Mol Sci. 2023 May 5;24(9):8278. doi: 10.3390/ijms24098278.
Neuropathic pain is a frequent feature of diabetic peripheral neuropathy (DPN) and small fiber neuropathy (SFN). Resolving the genetic architecture of these painful neuropathies will lead to better disease management strategies, counselling and intervention. Our aims were to profile ten sodium channel genes (SCG) expressed in a nociceptive pathway in painful and painless DPN and painful and painless SFN patients, and to provide a perspective for clinicians who assess patients with painful peripheral neuropathy. Between June 2014 and September 2016, 1125 patients with painful-DPN ( = 237), painless-DPN ( = 309), painful-SFN ( = 547) and painless-SFN ( = 32), recruited in four different centers, were analyzed for and variants by single molecule Molecular inversion probes-Next Generation Sequence. Patients were grouped based on phenotype and the presence of SCG variants. Screening of and revealed 125 different (potential) pathogenic variants in 194 patients (17.2%, = 194/1125). A potential pathogenic variant was present in 18.1% ( = 142/784) of painful neuropathy patients vs. 15.2% ( = 52/341) of painless neuropathy patients (17.3% ( = 41/237) for painful-DPN patients, 14.9% ( = 46/309) for painless-DPN patients, 18.5% ( = 101/547) for painful-SFN patients, and 18.8% ( = 6/32) for painless-SFN patients). Of the variants detected, 70% were in and . The frequency of and variants was the highest in painful-SFN patients, variants in painful-DPN patients, and variants in painless-DPN patients. Our findings suggest that rare SCG genetic variants may contribute to the development of painful neuropathy. Genetic profiling and SCG variant identification should aid in a better understanding of the genetic variability in patients with painful and painless neuropathy, and may lead to better risk stratification and the development of more targeted and personalized pain treatments.
神经性疼痛是糖尿病周围神经病变 (DPN) 和小纤维神经病 (SFN) 的常见特征。解析这些疼痛性神经病的遗传结构将导致更好的疾病管理策略、咨询和干预。我们的目的是分析在痛性和无痛性 DPN 和痛性和无痛性 SFN 患者的疼痛通路中表达的十个钠通道基因 (SCG),并为评估痛性周围神经病患者的临床医生提供一个视角。在 2014 年 6 月至 2016 年 9 月期间,我们分析了来自四个不同中心的 1125 名痛性-DPN 患者(=237)、无痛性-DPN 患者(=309)、痛性-SFN 患者(=547)和无痛性-SFN 患者(=32)中 和 变体的单分子分子反转探针-下一代序列。根据表型和 SCG 变体的存在,将患者分为不同的组。筛选 和 显示 194 名患者(17.2%,=194/1125)存在 125 种不同的(潜在)致病性变体。痛性神经病患者中存在潜在致病性变体的比例为 18.1%(=142/784),无痛性神经病患者为 15.2%(=52/341)(痛性-DPN 患者为 17.3%(=41/237),无痛性-DPN 患者为 14.9%(=46/309),痛性-SFN 患者为 18.5%(=101/547),无痛性-SFN 患者为 18.8%(=6/32)。在检测到的变体中,70%存在于 和 中。在痛性-SFN 患者中发现的 和 变体频率最高,在痛性-DPN 患者中发现 变体,在无痛性-DPN 患者中发现 变体。我们的发现表明,罕见的 SCG 遗传变体可能导致痛性神经病的发生。遗传分析和 SCG 变体鉴定应有助于更好地了解痛性和无痛性神经病患者的遗传变异性,并可能导致更好的风险分层和更有针对性和个性化的疼痛治疗。